

b) allowing said cell from step a) to develop into a transgenic mouse,

wherein said cell of step a) is a pronuclei of a fertilized oocyte, said method further comprising implanting said fertilized oocyte into a pseudopregnant mouse; or

wherein said cell of step a) is an embryonic stem cell; said DNA is integrated into a genomic DNA of said embryonic stem cell; and said embryonic stem cell is introduced into a developing embryo.

5. (Twice Amended) The method of claim 1, wherein said promoter is selected from the group consisting of alpha-myosin heavy chain promoter, keratin K14 promoter, and insulin promoter.

9. (Amended) The mouse produced by the method of claim 1.

12. (Amended) The mouse that is a descendant from the mouse according to claim 9.

14. (Twice Amended) The mouse according to Claim 9, wherein the mouse is homozygous with regard to the transgenic DNA.

15. (Amended) A cell isolated from a mouse according to claim 9.

18. (Twice Amended) A fertilized oocyte containing transgenic DNA that encodes a polypeptide comprising an amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.

19. (Amended) An embryonic stem cell containing transgenic DNA that encodes a polypeptide comprising an amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.

20. (Twice Amended) A method for identifying a compound as a PDGF-C antagonist, said method comprising the steps of:

introducing said compound into a transgenic mouse overexpressing a polypeptide comprising an amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2;

monitoring in vitro a biological activity of PDGF-C in an isolated cell from said mouse; and

identifying said compound as a PDGF-C antagonist where PDGF-C biological activity is inhibited.

22. (Twice Amended) A method for identifying a compound as a PDGF-C antagonist, said method comprising the steps of:

exposing to said compound a cell isolated from a transgenic mouse overexpressing a polypeptide comprising an amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2;

assaying an effect of said compound on said cell in vitro; and

identifying said compound as a PDGF-C antagonist where the PDGF-C biological activity of said cell is altered.

23. (Twice Amended) A method of screening a compound for inhibition of hypertrophy, comprising the steps of:

administering a pharmaceutically active amount of said compound to a transgenic mouse overexpressing a polypeptide comprising an amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2; and

monitoring cardiac development of said mouse;

determining said compound inhibits hypertrophy where said cardiac development is inhibited when compared to a control transgenic mouse in the absence of said compound.

24. (Twice Amended) A method of screening a compound for inhibition of fibrosis, comprising the steps of:

administering a pharmaceutically active amount of said compound to a transgenic mouse overexpressing a polypeptide comprising an amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2; and

monitoring the cardiac development of said mouse;

determining said compound inhibits fibrosis where said cardiac development is inhibited when compared to a non-treated control transgenic mouse.

25. A transgenic mouse according to Claim 9, wherein the mouse is heterozygous with regard to the transgenic DNA encoding a polypeptide comprising an amino acid sequence SEQ ID NO:1 or SEQ ID NO:2.

IN THE ABSTRACT:

Please substitute the new Abstract of the Disclosure submitted herewith on a separate page for the original Abstract presently in the application.

(Applicant's Remarks are set forth hereinbelow, starting on the following page.)